Fifth Third Bancorp Raises Position in Edwards Lifesciences Corporation $EW

Fifth Third Bancorp grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,870 shares of the medical research company’s stock after purchasing an additional 1,865 shares during the period. Fifth Third Bancorp’s holdings in Edwards Lifesciences were worth $1,867,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Arlington Trust Co LLC lifted its holdings in shares of Edwards Lifesciences by 1.2% during the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock valued at $804,000 after purchasing an additional 135 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 2.8% during the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 142 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Edwards Lifesciences by 9.3% during the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 145 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the last quarter. Finally, Leo Wealth LLC lifted its holdings in shares of Edwards Lifesciences by 1.2% during the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock valued at $905,000 after purchasing an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $76.34 on Friday. The stock has a 50-day simple moving average of $78.50 and a two-hundred day simple moving average of $75.72. The firm has a market capitalization of $44.82 billion, a P/E ratio of 10.98, a PEG ratio of 3.67 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.